Clinical trials: Regorafenib
Hepatocellular Carcinoma
Adoptive Autologous iNKT Cells for the Treatment of Progressed Hepatocellular Carcinoma Continuing on PD-1 Inhibitor Therapy
The goal of this clinical trial is to explore the efficacy and safety of autologous iNKT cells in patients with progressed hepatocellular carcinoma (HCC) after treatment with PD-1 antibody.
- Trial name
- NCT05962450
- Testing
- iNKT Cells, PD-1, Regorafenib
- Where
- China
- Volunteers
- 84 people
- Sponsor
- Beijing YouAn Hospital
Esophagogastric Cancer, HER2-Negative
A Study of Nivolumab Combined With FOLFOX and Regorafenib in People Who Have HER2-Negative Esophagogastric Cancer
The purpose of this study is to find out whether combining nivolumab, FOLFOX, and regorafenib may be a safe and effective treatment for people who have HER2-negative metastatic esophagogastric cancer.
- Trial name
- NCT04757363
- Testing
- regorafenib, nivolumab, FOLFOX chemotherapy with oxaliplatin
- Where
- 7 sites in United States
- Volunteers
- 39 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
This multi-site, Phase 1/2 clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO212 alone for the treatment of patients with radiographically-confirmed…
- Conditions
- Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult, Cervical Cancer
- Trial name
- NCT06047379
- Testing
- NEO212 Oral Capsule, Ipilimumab, Pembrolizumab
- Where
- 8 sites in United States
- Volunteers
- 134 people
- Sponsor
- Neonc Technologies, Inc.
MSI-H Colorectal Cancer
Regorafenib in Combination With Pembrolizumab or Pembrolizumab for MSI-H Colorectal Cancer
This is a trial of Regorafenib in combination with pembrolizumab for patients with MSI-H colorectal cancer consisting of lead-in phase examining preliminary efficacy and safety, followed by a randomized phase to further examine…
- Trial name
- NCT06006923
- Testing
- Regorafenib, Pembrolizumab
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Anwaar Saeed
Unresectable Hepatocellular Carcinoma, Hepatocellular Carcinoma
Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma
The purpose of this study is to determine the effects that Regorafenib in combination with Yttrium-90 (Y-90) radioembolization has on patients with unresectable hepatocellular carcinoma.
- Trial name
- NCT06902246
- Testing
- Regorafenib, TheraSphere™ Yttrium-90 Trans-Arterial Radioembolization
- Sponsor
- University of Miami
Hepatocellular Carcinoma
Carelizumab Combined With Regorafenib in the Treatment of HCC（CARE-2020）
To investigate the efficacy and safety of carelizumab combined with regorafenib in second-line treatment for patients with primary hepatocellular carcinoma.
- Trial name
- NCT04806243
- Testing
- Regorafenib Pill&Camrelizumab
- Where
- China
- Volunteers
- 69 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Metastatic Biliary Tract Carcinoma
A Phase 2 Trial of Regorafenib as A Single Agent in Advanced and Metastatic Biliary Tract Carcinoma/Cholangiocarcinoma Patients Who Have Failed First-line Chemotherapy
Based on the facts of multiple pathways involvement in cholangiocarcinoma tumor genesis, including EGFR, Ras, Raf, VEGFR, and PDGFR, with evidence of overexpression of these proteins associated with tumor stage, prognosis and…
- Trial name
- NCT02053376
- Testing
- Regorafenib
- Where
- United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Nathan Bahary, MD
Advanced Gastrointestinal Stromal Tumor
An Observational Study to Learn More About Treatment With Regorafenib in People With Advanced Gastrointestinal Stromal Tumors in the United States
This is an observational study in which data already collected from people with advanced gastrointestinal stromal tumors are studied.
- Trial name
- NCT06321055
- Testing
- Regorafenib (Stivarga, BAY73-4506)
- Where
- United States
- Volunteers
- 136 people
- Sponsor
- Bayer
CRC (Colorectal Cancer)
Study of Ruxolitinib in Colorectal Cancer Patients
The purpose of this study was to determine if ruxolitinib, in combination with regorafenib, is safe and effective in the treatment of metastatic colorectal cancer.
- Trial name
- NCT02119676
- Testing
- Ruxolitinib, Regorafenib
- Where
- 86 sites in United States, Australia and 6 more
- Volunteers
- 396 people
- Sponsor
- Incyte Corporation
Osteosarcoma, Ewing Sarcoma of Bone
Regorafenib in Patients With Refractory Primary Bone Tumors
The aim of the project is to improve treatment outcomes in patients with primary malignant bone tumors, refractory to standard therapy, by increasing the availability of advanced therapy, as well as to develop treatment options…
- Trial name
- Regbone (NCT05395741)
- Testing
- Regorafenib
- Where
- 2 sites in Poland
- Volunteers
- 30 people
- Sponsor
- Institute of Mother and Child, Warsaw, Poland
Pancreas Cancer, Ovarian Cancer
Regorafenib in Patients With Metastatic Solid Tumors Who Have Progressed After Standard Therapy
This is a single arm, single-stage, phase II trial to evaluate the activity of Regorafenib in patients with metastatic solid tumors (pancreatic cancer, ovarian cancer, melanoma, sarcoma, thymoma (type B2 - B3) and thymic…
- Conditions
- Pancreas Cancer, Ovarian Cancer, Melanoma, Sarcoma
- Trial name
- RESOUND (NCT02307500)
- Testing
- Regorafenib
- Where
- Italy
- Volunteers
- 82 people
- Sponsor
- Istituto Clinico Humanitas
Colorectal Cancer, Liver Metastases
Serplulimab+Regorafenib +Hepatic Artery Bicarbonate Infusion in Patients With Colorectal Cancer and Liver Metastases
A single-center, single-arm, phase 2 trial of Serplulimab in combination with Regorafenib and hepatic artery bicarbonate infusion for third-line treatment in patients with colorectal cancer and liver metastases.
- Trial name
- NCT05894837
- Testing
- Serplulimab+Regorafenib, Hepatic Artery Bicarbonate Infusion
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Carcinoma, Hepatocellular
Regorafenib Plus Pembrolizumab in First Line Systemic Treatment of HCC
This study will determine if the combination of regorafenib and pembrolizumab is safe and tolerated in patients with advanced liver cancer.
- Trial name
- NCT03347292
- Testing
- Regorafenib(Stivarga, BAY73-4506), Pembrolizumab
- Where
- 7 sites in United States, Germany
- Volunteers
- 58 people
- Sponsor
- Bayer
Colorectal Cancer Metastatic
STREAM-2: Second-line Treatment With REgorafenib in Advanced RAS-Mutant Colorectal Cancer
The investigators hypothesize that patients with mCRC RAS-mutant eligible for a second line treatment with good prognostic features, identified as single metastatic site, long progression free survival (PFS) in first line…
- Trial name
- NCT07213570
- Testing
- standard second line treatment, at discretion of the investigator, Regorafenib (BAY73-4506)
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute, Naples
Ewing Sarcoma
Phase Ib / Regorafenib With Conventional Chemotherapy/Newly Diagnosed Patients/ Multimetastatic Ewing Sarcoma
New drug efficacy in ES has been disappointing in the last decades and no new drugs have been successfully introduced up to now in front line treatment.
- Trial name
- REGO-INTER-EWI (NCT05830084)
- Testing
- regorafenib tablet
- Where
- 13 sites in Australia, Denmark and 4 more
- Volunteers
- 23 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Adenoid Cystic Carcinoma
Regorafenib in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Regorafenib is an oral medication that can interfere with cancer cell growth and reduce the growth of blood vessels around tumors.
- Trial name
- NCT02098538
- Testing
- Regorafenib
- Where
- 5 sites in United States
- Volunteers
- 38 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Stage IB Hepatocellular Carcinoma AJCC v8, Stage II Hepatocellular Carcinoma AJCC v8
Regorafenib and Durvalumab for the Treatment of High-Risk Liver Cancer
This phase II trial tests whether regorafenib and durvalumab work to shrink tumors in patients with high-risk liver cancer. Regorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Conditions
- Stage IB Hepatocellular Carcinoma AJCC v8, Stage II Hepatocellular Carcinoma AJCC v8, Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8
- Trial name
- NCT05194293
- Testing
- Durvalumab, Regorafenib
- Where
- 3 sites in United States
- Volunteers
- 4 people
- Sponsor
- Academic and Community Cancer Research United
Colorectal Cancer
A Study to Investigate Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy Versus Regorafenib in Participants With Metastatic Colorectal Adenocarcinoma (COTEZO IMblaze370)
This is a Phase III, multicenter, open-label, three-arm, randomized study in participants with unresectable locally advanced or metastatic colorectal cancer (CRC) who have received at least two prior regimens of cytotoxic…
- Trial name
- NCT02788279
- Testing
- Atezolizumab (MPDL3280A), an Engineered Anti-PDL1 Antibody, Cobimetinib, Regorafenib
- Where
- 73 sites in United States, Australia and 9 more
- Volunteers
- 363 people
- Sponsor
- Hoffmann-La Roche
Advanced Hepatocellular Carcinoma
Regorafenib Plus Tislelizumab as First-line Systemic Therapy for Patients With Advanced Hepatocellular Carcinoma
Combination of anti-angiogenic molecular targeted therapy and anti- programmed cell death -1 immune checkpoint inhibitor (ICI) therapy has shown promising antitumor activity in multiple cancer types, including patients with…
- Trial name
- NCT04183088
- Testing
- Tislelizumab+regorafenib for part 1;Tislelizumab+regorafenib for group 1 of part 2; Regorafenib for group 2 of part 2.
- Where
- Taiwan
- Volunteers
- 125 people
- Sponsor
- National Taiwan University Hospital
Gastrointestinal Stromal Tumors
WB-DWI for Early Prediction of Therapy Response in Patients With Advanced Metastatic GIST Treated With Regorafenib
The purpose of this study is to evaluate WB DWI as early predictor of response to treatment with regorafenib or placebo in patients with advanced metastatic GIST.
- Trial name
- NCT01265979
- Testing
- Whole body diffusion MRI
- Where
- Belgium
- Volunteers
- 5 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven